PA8528101A1 - PIRAZOL DERIVATIVES - Google Patents

PIRAZOL DERIVATIVES

Info

Publication number
PA8528101A1
PA8528101A1 PA20018528101A PA8528101A PA8528101A1 PA 8528101 A1 PA8528101 A1 PA 8528101A1 PA 20018528101 A PA20018528101 A PA 20018528101A PA 8528101 A PA8528101 A PA 8528101A PA 8528101 A1 PA8528101 A1 PA 8528101A1
Authority
PA
Panama
Prior art keywords
compounds
formula
syndrome
deterioration
pharmaceutical compositions
Prior art date
Application number
PA20018528101A
Other languages
Spanish (es)
Inventor
Christopher Blair Cooper
Christopher John Helal
Mark Allen Sanner
Travis T Wager
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PA8528101A1 publication Critical patent/PA8528101A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Psychiatry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

LA INVENCION PROPORCIONA COMPUESTOS DE LA FORMULA 1 DONDE R1, R2, R3, Y R4 SON COMO SE DEFINEN, Y SUS SALES FARMACEUTICAMENTE ACEPTABLES. SE INDICA QUE LOS COMPUESTOS DE FORMULA 1 TIENEN ACTIVIDAD PARA INHIBIR LAS cdk5, cdk2 GSK-3. PROPORCIONA COMPOSICIONES FARMACEUTICAS Y METODOS QUE COMPRENDEN COMPUESTOS DE FORMULA 1 PARA TRATAR Y PREVENIR ENFERMEDADES Y CONDICIONES QUE IMPLICAN CRECIMIENTO CELULAR ANORMAL, TALES COMO EL CANCER, Y ENFERMEDADES Y CONDICIONES NEURODEGENERATIVAS Y LAS AFECTADAS POR NEUROTRASMISION DE LA DOPAMINA. TAMBIEN SE DESCRIBEN COMPOSICIONES FARMACEUTICAS Y METODOS QUE COMPRENDEN COMPUESTOS DE FORMULA 1 PARA TRATAR FERTILIDAD MASCULINA Y LA MOTILIDAD ESPERMATICA; DIABETES MELLITUS; DETERIORO DE LA TOLERANCIA A LA GLUCOSA; SINDROME METABOLICO O SINDROME X; SINDROME DE POLIQUISTOSIS OVARICA, ADIPOGENESIS Y OBESIDAD; MIOGENESIS Y FRAGILIDAD, POR EJEMPLO EL DETERIORO DE LAS CARACTERISTICAS FISICAS RELACIONADO CON LA EDAD; SARCOPENIA AGUDA, POR EJEMPLO ATROFIA MUSCULAR Y/O CAQUEXIA ASOCIADA CON LAS QUEMADURAS, REPOSO EN CAMA, INMOVILIZACION DE MIEMBROS, O IMPORTANTE CIRUGIA TORACICA, ABDOMINAL, Y/O ORTOPEDICA; SEPSIS; CAIDA DEL CABELLO, CABELLO RALO Y CALVICIE; E INMUNODEFICIENCIA.THE INVENTION PROVIDES COMPOUNDS OF FORMULA 1 WHERE R1, R2, R3, AND R4 ARE AS DEFINED, AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS. IT IS INDICATED THAT THE COMPOUNDS OF FORMULA 1 HAVE ACTIVITY TO INHIBIT THE CDK5, CDK2 GSK-3. PROVIDES PHARMACEUTICAL COMPOSITIONS AND METHODS THAT INCLUDE FORMULA 1 COMPOUNDS TO TREAT AND PREVENT DISEASES AND CONDITIONS THAT IMPLICATE ABNORMAL CELLULAR GROWTH, SUCH AS CANCER, AND NEURODEGENERATIVE DISEASES AND CONDITIONS OF NEOPODRASTRUCTURE AND AFFECTANCE. PHARMACEUTICAL COMPOSITIONS AND METHODS THAT INCLUDE FORMULA 1 COMPOUNDS TO TREAT MALE FERTILITY AND SPERMAL MOTILITY ARE ALSO DESCRIBED; MELLITUS DIABETES; DETERIORATION OF GLUCOSE TOLERANCE; METABOLIC SYNDROME OR X SYNDROME; OVARICA POLYCHYSTOSIS, ADIPOGENESIS AND OBESITY SYNDROME; MIOGENESIS AND FRAGILITY, FOR EXAMPLE THE DETERIORATION OF PHYSICAL CHARACTERISTICS RELATED TO AGE; ACUTE SARCOPENIA, FOR EXAMPLE MUSCULAR ATROPHY AND / OR CAQUEXY ASSOCIATED WITH BURNS, BED REST, IMMOBILIZATION OF MEMBERS, OR IMPORTANT TORACICA SURGERY, ABDOMINAL, AND / OR ORTHOPEDIC; SEPSIS; HAIR FALL, RALO AND CALVICIE HAIR; AND IMMUNODEFICIENCY.

PA20018528101A 2000-08-31 2001-08-31 PIRAZOL DERIVATIVES PA8528101A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US22941500P 2000-08-31 2000-08-31

Publications (1)

Publication Number Publication Date
PA8528101A1 true PA8528101A1 (en) 2002-07-30

Family

ID=22861151

Family Applications (1)

Application Number Title Priority Date Filing Date
PA20018528101A PA8528101A1 (en) 2000-08-31 2001-08-31 PIRAZOL DERIVATIVES

Country Status (38)

Country Link
EP (1) EP1313710A1 (en)
JP (1) JP2004507526A (en)
KR (1) KR20030027093A (en)
CN (1) CN1518543A (en)
AP (1) AP2001002266A0 (en)
AR (1) AR035345A1 (en)
AU (1) AU2001280009A1 (en)
BG (1) BG107455A (en)
BR (1) BR0113574A (en)
CA (1) CA2420363A1 (en)
CR (1) CR6881A (en)
CZ (1) CZ2003468A3 (en)
DO (1) DOP2001000243A (en)
DZ (1) DZ3398A1 (en)
EA (1) EA200300205A1 (en)
EC (1) ECSP034480A (en)
EE (1) EE200300085A (en)
GT (1) GT200100179A (en)
HN (1) HN2001000192A (en)
HR (1) HRP20030140A2 (en)
HU (1) HUP0302669A3 (en)
IL (1) IL154016A0 (en)
IS (1) IS6687A (en)
MA (1) MA26946A1 (en)
MX (1) MXPA03001785A (en)
NO (1) NO20030958L (en)
NZ (1) NZ523656A (en)
OA (1) OA12368A (en)
PA (1) PA8528101A1 (en)
PE (1) PE20020470A1 (en)
PL (1) PL360742A1 (en)
SK (1) SK2002003A3 (en)
SV (1) SV2002000618A (en)
TN (1) TNSN01132A1 (en)
UY (1) UY26909A1 (en)
WO (1) WO2002018346A1 (en)
YU (1) YU14703A (en)
ZA (1) ZA200301064B (en)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
EP2298311B1 (en) 1999-01-13 2012-05-09 Bayer HealthCare LLC w-Carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
AU2001292670A1 (en) 2000-09-15 2002-03-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6613776B2 (en) 2000-09-15 2003-09-02 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6660731B2 (en) 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6610677B2 (en) 2000-09-15 2003-08-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
BR0116411A (en) 2000-12-21 2003-11-11 Vertex Pharma Pyrazole compounds useful as protein kinase inhibitors
WO2003026649A1 (en) * 2001-09-27 2003-04-03 Applied Research Systems Ars Holding N.V. Methods of increasing endogenous testosterone levels
US20030216396A1 (en) 2002-02-11 2003-11-20 Bayer Corporation Pyridine, quinoline, and isoquinoline N-oxides as kinase inhibitors
MXPA04007832A (en) 2002-02-11 2005-09-08 Bayer Pharmaceuticals Corp Aryl ureas with angiogenesis inhibiting activity.
JP2006501191A (en) * 2002-07-17 2006-01-12 ファルマシア・イタリア・エス・ピー・エー Heterobicyclic pyrazole derivatives as kinase inhibitors
BR0315158A (en) 2002-10-09 2005-08-16 Pfizer Prod Inc Pyrazole Compounds for the Treatment of Neurodegenative Disorders
AU2003301302A1 (en) * 2002-10-15 2004-05-04 Smithkline Beecham Corporation Pyradazine compounds as gsk-3 inhibitors
ATE410415T1 (en) * 2003-02-27 2008-10-15 Smithkline Beecham Corp NEW CONNECTIONS
CA2526617C (en) 2003-05-20 2015-04-28 Bayer Pharmaceuticals Corporation Diaryl ureas with kinase inhibiting activity
JP4220548B2 (en) * 2003-06-05 2009-02-04 エラン ファーマシューティカルズ，インコーポレイテッド Acylated amino acids, amidylpyrazole, and related compounds
PL1651612T3 (en) * 2003-07-22 2012-09-28 Astex Therapeutics Ltd 3,4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases (cdk) and glycogen synthase kinase-3 (gsk-3) modulators
UA84156C2 (en) 2003-07-23 2008-09-25 Байер Фармасьютикалс Корпорейшн Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions
MXPA06000933A (en) * 2003-07-25 2006-03-30 Pfizer Aminopyrazole compounds and use as chk1 inhibitors.
WO2005051919A1 (en) * 2003-11-26 2005-06-09 Pfizer Products Inc. Aminopyrazole derivatives as gsk-3 inhibitors
US7244757B2 (en) * 2004-04-01 2007-07-17 Pfizer Inc Pyrazole-amine compounds for the treatment of neurodegenerative disorders
US20090227648A1 (en) * 2004-04-21 2009-09-10 Astrazeneca Ab Pyrazole derivatives useful for the treatment of cancer
EP1751139B1 (en) 2004-04-30 2011-07-27 Bayer HealthCare LLC Substituted pyrazolyl urea derivatives useful in the treatment of cancer
US7498342B2 (en) 2004-06-17 2009-03-03 Plexxikon, Inc. Compounds modulating c-kit activity
EP1781637A1 (en) 2004-06-29 2007-05-09 Rigel Pharmaceuticals, Inc. 2-substituted quinoline compounds and their uses as inhibitors of the ige receptor signaling cascade
US7491720B2 (en) 2004-10-29 2009-02-17 Banyu Pharmaceutical Co., Ltd. Aminopyridine derivatives having Aurora A selective inhibitory action
EP1812424A4 (en) 2004-11-17 2009-07-08 Miikana Therapeutics Inc Kinase inhibitors
AR054425A1 (en) 2005-01-21 2007-06-27 Astex Therapeutics Ltd PIPERIDIN ADDITION SALTS 4-IL-ACID AMID 4- (2,6-DICLORO-BENZOILAMINO) 1H-PIRAZOL-3-CARBOXILICO.
US8404718B2 (en) 2005-01-21 2013-03-26 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors
RS52061B (en) 2005-02-04 2012-04-30 Astrazeneca Ab Pyrazolylaminopyridine derivatives useful as kinase inhibitors
US20090156582A1 (en) * 2005-02-09 2009-06-18 Tetsuya Tsukamoto Pyrazole Compound
WO2006087530A1 (en) 2005-02-16 2006-08-24 Astrazeneca Ab Chemical compounds
EP1899323A2 (en) 2005-05-16 2008-03-19 AstraZeneca AB Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors
EP1741708A1 (en) * 2005-06-28 2007-01-10 Sanofi-Aventis Deutschland GmbH Heteroaryl-substituted amides comprising an unsaturated or cyclic linker group, and their use as pharmaceuticals
EP2258357A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
JP2009506069A (en) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド Neurogenesis through modulation of muscarinic receptors
WO2007041358A2 (en) 2005-09-30 2007-04-12 Miikana Therapeutics, Inc. Substituted pyrazole compounds
AU2006304787A1 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by PDE inhibition
BRPI0618011A2 (en) 2005-10-28 2011-08-16 Astrazeneca Ab compound or a pharmaceutically acceptable salt thereof, process for the preparation thereof, pharmaceutical composition, use of a compound or a pharmaceutically acceptable salt thereof, and methods for producing an antiproliferative effect and a pro-apoptotic effect in an animal warm-blooded to treat disease and to produce a jak inhibiting effect on a warm-blooded animal
US20070112017A1 (en) 2005-10-31 2007-05-17 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
CN101316843B (en) 2005-11-03 2013-01-02 顶点医药品公司 Aminopyrimidines useful as kinase inhibitors
US7572809B2 (en) * 2005-12-19 2009-08-11 Hoffmann-La Roche Inc. Isoquinoline aminopyrazole derivatives
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
EP2021000A2 (en) 2006-05-09 2009-02-11 Braincells, Inc. Neurogenesis by modulating angiotensin
BRPI0717439A2 (en) * 2006-10-18 2013-11-19 Periness Ltd PHARMACEUTICAL COMPOSITION, AND METHODS FOR TREATING MALE SUBFERTILITY, FOR DETERMINING A FERTLITY STATUS IN A MALE SEX, FOR ASSISTED REPRODUCTION TECHNIQUE FOR A SPECULAR SPULLET REPRODUCTION FOR CULLED SPLIT USE IN AN AUXILIARY REPRODUCTION TECHNIQUE.
KR20090071662A (en) 2006-10-21 2009-07-01 애보트 게엠베하 운트 콤파니 카게 Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
US7737149B2 (en) * 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
KR20090112722A (en) 2007-01-24 2009-10-28 글락소 그룹 리미티드 Pharmaceutical compositions comprising 3,5-diamino-6-2,3-dichl0rophenyl-1,2,4-triazine or r--2,4-diamino-5-2,3-dichlorophenyl-6-fluoromethyl pyrimidine and an nk1
US20100190777A1 (en) 2007-07-17 2010-07-29 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
WO2009017453A1 (en) * 2007-07-30 2009-02-05 Astrazeneca Ab New therapeutic combination of an antipsychotic and a gsk3 inhibitor 958
MX2010002772A (en) 2007-09-21 2010-03-31 Array Biopharma Inc Pyridin-2 -yl-amino-i, 2, 4 -thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus.
WO2009130900A1 (en) * 2008-04-24 2009-10-29 日本曹達株式会社 Oxime derivative, intermediate compound, and plant disease control agent
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
CR20170089A (en) 2009-04-03 2017-07-17 Plexxikon Inc PROPANE-ACID COMPOSITIONS-1 - SULFONIC {3- [5- (4-CHLORINE-PHENYL) -1H-PIRROLO [2,3-B] PIRIDINA-3-CARBONIL] -2,4-DIFLUORO-PHENIL} -AMIDA AND THE USE OF THE SAME
JP2013506691A (en) * 2009-10-02 2013-02-28 バーテックス ファーマシューティカルズ インコーポレイテッド Pyrazole inhibitors of phosphatidylinositol 3-kinase
NZ599866A (en) 2009-11-06 2014-09-26 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
US9266855B2 (en) 2010-09-27 2016-02-23 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
US9090592B2 (en) 2010-12-30 2015-07-28 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
MA34948B1 (en) 2011-02-07 2014-03-01 Plexxikon Inc COMPOUNDS AND METHODS FOR MODULATING KINASE, AND INDICATIONS THEREOF
TWI558702B (en) 2011-02-21 2016-11-21 普雷辛肯公司 Solid forms of a pharmaceutically active substance
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
JP6545681B2 (en) 2013-08-16 2019-07-17 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 3-substituted cyclopentyl amine derivative
CN106580986B (en) * 2016-11-28 2017-09-15 王保亮 A kind of pharmaceutical composition for treating teen bra
MX2021007925A (en) 2018-12-31 2021-10-26 Biomea Fusion Llc Irreversible inhibitors of menin-mll interaction.
EP3906029A4 (en) 2018-12-31 2022-09-21 Biomea Fusion, LLC Inhibitors of menin-mll interaction
JP7094456B2 (en) * 2019-01-31 2022-07-01 ファイザー・インク CDK2 inhibitor
TW202229268A (en) * 2020-12-22 2022-08-01 大陸商上海拓界生物醫藥科技有限公司 Cdk2 inhibitor and preparation method thereof
UY39832A (en) 2021-06-28 2023-01-31 Blueprint Medicines Corp CDK2 INHIBITORS
TW202317564A (en) * 2021-07-01 2023-05-01 大陸商上海拓界生物醫藥科技有限公司 Cdk2 inhibitor, a preparation method and a use thereof
TW202325280A (en) * 2021-11-09 2023-07-01 大陸商上海拓界生物醫藥科技有限公司 An aminopyrazole derivative, preparation method and use thereof
WO2023092088A1 (en) * 2021-11-19 2023-05-25 Blueprint Medicines Corporation Cdk2 inhibitors and methods of making and using same
WO2023239629A1 (en) * 2022-06-06 2023-12-14 Plexium, Inc. Compounds and pharmaceutical compositions that degrade cdk2

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ505844A (en) * 1997-12-22 2003-10-31 Bayer Ag Inhibition of raf kinase using substituted heterocyclic ureas
KR100579792B1 (en) * 1998-05-13 2006-05-12 동화약품공업주식회사 Novel 2,5-pyridinedicarboxylic acid derivatives
GB9811427D0 (en) * 1998-05-29 1998-07-22 Zeneca Ltd Chemical compounds
AU6314900A (en) * 1999-07-26 2001-02-13 Banyu Pharmaceutical Co., Ltd. Biarylurea derivatives
US6387900B1 (en) * 1999-08-12 2002-05-14 Pharmacia & Upjohn S.P.A. 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents
BR0013143A (en) * 1999-08-12 2002-06-11 Pharmacia Italia Spa 3 (5) amino pyrazole derivatives, process for their preparation and use as antitumor agents
CZ20021703A3 (en) * 1999-11-30 2003-06-18 Pfizer Products Inc. 2,4-Diaminopyrimidine compounds usable as immunosuppressants
EP1274706A1 (en) * 2000-04-18 2003-01-15 Agouron Pharmaceuticals, Inc. Pyrazoles for inhibiting protein kinases

Also Published As

Publication number Publication date
YU14703A (en) 2006-05-25
CZ2003468A3 (en) 2004-05-12
HUP0302669A2 (en) 2003-12-29
MXPA03001785A (en) 2003-06-04
EE200300085A (en) 2004-12-15
PL360742A1 (en) 2004-09-20
NO20030958D0 (en) 2003-02-28
HRP20030140A2 (en) 2003-04-30
MA26946A1 (en) 2004-12-20
DZ3398A1 (en) 2002-03-07
BR0113574A (en) 2003-07-22
BG107455A (en) 2003-09-30
WO2002018346A1 (en) 2002-03-07
ZA200301064B (en) 2004-04-19
CN1518543A (en) 2004-08-04
NZ523656A (en) 2004-11-26
IL154016A0 (en) 2003-07-31
CA2420363A1 (en) 2002-03-07
ECSP034480A (en) 2003-03-31
SK2002003A3 (en) 2004-04-06
PE20020470A1 (en) 2002-06-18
DOP2001000243A (en) 2002-10-15
AP2001002266A0 (en) 2001-09-30
JP2004507526A (en) 2004-03-11
NO20030958L (en) 2003-02-28
KR20030027093A (en) 2003-04-03
UY26909A1 (en) 2002-03-22
EP1313710A1 (en) 2003-05-28
GT200100179A (en) 2002-04-22
AU2001280009A1 (en) 2002-03-13
TNSN01132A1 (en) 2005-11-10
SV2002000618A (en) 2002-10-24
OA12368A (en) 2004-04-13
EA200300205A1 (en) 2003-06-26
HUP0302669A3 (en) 2004-03-29
CR6881A (en) 2004-03-11
AR035345A1 (en) 2004-05-12
HN2001000192A (en) 2001-08-28
IS6687A (en) 2003-01-16

Similar Documents

Publication Publication Date Title
PA8528101A1 (en) PIRAZOL DERIVATIVES
PA8523701A1 (en) IMIDAZOL DERIVATIVES
BR0201691A (en) Thiazole Derivatives
UY28922A1 (en) RECEIVER CB1 LINKS USEFUL IN THE TREATMENT OF PAIN AND / OR OTHER SYMPTOMS OR RELATED DISEASES; PHARMACEUTICAL COMPOUNDS AND THEIR PREPARATION.
CU23208A3 (en) OXAZOLIDINONAS REPLACED AND ITS USE IN THE FIELD OF THE SANGUINEA COAGULATION
UY26782A1 (en) DERIVATIVES OF BENZOTIAZOLE
ES2552764T3 (en) Methods for the treatment of various diseases and conditions, and compounds useful for them
JPH09503996A (en) Pyrazolopyrimidinones for the treatment of impotence
EP1609798A4 (en) Fused heterocyclic derivative, medicinal composition containing the same, and medicinal use thereof
PA8593101A1 (en) COMPOSITIONS FOR THE TREATMENT OF ABNORMAL CELL GROWTH
CY1117094T1 (en) 2-PHENYLHYTHLAMINE PRODUCER AS MODIFICATIONS OF CALCIUM AND / OR Sodium
NO20081844L (en) Therapeutic compounds
ES2182903T3 (en) USEFUL HETEROCICLICAL DERIVATIVES IN THE TREATMENT OF ALLERGIC OR Rheumatic Diseases, THEIR PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
ES2351665T3 (en) BENZAMIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF MUCOSITIS.
GT199100051A (en) PHARMACEUTICAL COMPOSITIONS AND METHODS FOR RELIEF SYMPTOMS OF GASTROINTESTINAL PAIN INDUCED BY NON-STEROID ANTI-INFLAMMATORY DRUGS
DK0527081T3 (en) Newly substituted 3-piperazinylalkyl-2,3-dihydro-1,3-4H-benzoxazin-4-ones, their preparation and therapeutic use
AR044712A1 (en) DERIVATIVES OF INDOL, PROCEDURES FOR THE PREPARATION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND THEIR EMPLOYMENT IN THE MANUFACTURE OF MEDICINES.
PT1157015E (en) USE OF POLYCYCLIC 2-AMINO-TRIAZOLE SYSTEMS FOR THE PREPARATION OF MEDICINES FOR THE TREATMENT OF LIPOMETABOLIC PERTURBACOES, OBESITY AND TYPE II DIABETES
AR036009A1 (en) PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF VISCERAL PAIN AND GASTROINTESTINAL DISORDERS THAT INCLUDE A BICYCLIC AMINO ACID COMPOUND AND USE OF THIS LAST TO MANUFACTURE SUCH PHARMACEUTICAL COMPOSITION
NO20021337D0 (en) 4-Benzylaminoquinoline Conjugates with Bile Acid and Their Heteroanalogs, Procedures for their Preparation, Drugs Containing These Compounds and Their Use
PE20030236A1 (en) DERIVATIVES OF BENZIMIDAZOLE 1-ARIL-2-N, S- OR O-SUBSTITUTES, OBTAINING DRUGS AND PHARMACEUTICAL PREPARATIONS CONTAINING THESE DERIVATIVES
AR121828A1 (en) PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION COMPRISING AMINOPYRIMIDINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT, HYDRATE OR SOLVATE THEREOF
BR0314930A (en) Pyrazole derivatives and their use as therapeutic agents for HIV-mediated diseases.
UY29135A1 (en) DERIVATIVES OF N-METHYLBENZENOSULFONAMIDE 4 AND N SUBSTITUTES, PREPARATION PROCEDURES, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND APPLICATIONS
BR0008559A (en) Polycyclic thiazol-2-ilidene amines, processes for their preparation and use as medicine